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Abstract 
 
Due to SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) being a 
novel virus, there are currently no known effective antiviral drugs capable of slowing its 
progress. To accelerate the discovery of potential drug candidates, bioinformatics based in 
silico drug discovery can be applied as a very robust tool. In the present study, more than 60 
antiviral drugs already available on the market, were chosen after literature survey. These can 
be used in clinical trials for the treatment of COVID-19. In this study, these candidate drugs 
were ranked based on their potential to interact with the Spike protein and RdRp (RNA-
dependent RNA polymerase) of SARS-CoV-2. Additionally, the mechanism of their action as 
well as how the virus infection can utilize Hemoglobin to decrease the oxygen level in blood 
is explained. Moreover, multiple sequence alignments of the Spike protein with 75 sequences 
of different viruses from the Orthocoronavirinae subfamily were performed. This gives insight 
into the evolutionarily conserved domains that can be targeted using drug or antibody 
treatment. This multidimensional study opens a new layer of understanding about the most 
effective drug-targetable sites on the Spike protein of SARS-CoV-2.  
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Introduction 
In the past two decades, the world has faced several infectious disease outbreaks such 
as Influenza A (H1N1), SARS, MERS, Ebola, and Zika virus, which have had a considerable 
global impact on the healthcare delivery and economic systems. More recently, the outbreak 
of novel coronavirus / 2019-nCov / SARS-CoV-2, a newly discovered virus from the 
coronavirus family that causes COVID-19, has spread worldwide from the Chinese city of 
Wuhan (Cui, Li et al. 2019; Andersen, Rambaut et al. 2020; Shereen, Khan et al. 2020). SARS-
CoV-2 is a highly transmittable coronavirus strain that can cause severe biological responses 
in among others the lower portion of the respiratory tract. Through the collection of 
epidemiological data, healthcare authorities have been able to determine the route through 
which person-to-person transmission of SARS-COV-19 has taken place, spreading at such high 
rates that it has become a worldwide public health challenge (Shereen, Khan et al. 2020). Many 
patients who tested positive for SARS-COV-19 who also had underlying comorbidity, have 
developed pneumonia-like symptoms. Especially elderly and patients with a compromised 
immune function, seem to be more susceptible to infection and subsequent mortality. In these 
high-risk patients, COVID-19 presents itself with flu-like symptoms which then rapidly worsen 
into severe pulmonary edema, respiratory distress blood thickening result stoke or cardiac 
arrest impose a serious threat to the life of COVID-19 patients (Avula, Nalleballe et al. 2020; 
Baldi, Sechi et al. 2020; Li and Ma 2020; Richardson, Hirsch et al. 2020) . Recently researchers 
also reported severe neurological problems in these patients which put a huge risk to the mental 
health in the society (Helms, Kremer et al. 2020; Mao, Jin et al. 2020). According to the latest 
report from the WHO (World Health Organization), up to the present, 27.7 million people were 
infected with COVID-19 and the death toll has reached 900 thousand worldwide. Of these, the 
American and European continents cover 6.3 million and 2.5 million cases respectively; 
together comprising around one third of known cases throughout the world. Despite cautious 
optimism related to the recent decline in cases and subsequent relaxation of containment 
procedures in various cities, there is still a fear of new waves of infections. Therefore, 
discovering an effective inhibitor of SARS-CoV-2 is urgently needed to protect human lives. 
 
During the early stages of the global COVID-19 crisis, doctors scrambled to find an effective 
treatment for those suffering as a result of the coronavirus infection. Researchers are trying to 
develop and establish various treatment modalities such as plasma therapy, antibody treatment, 
decoy peptides/molecules and vaccine development (Duan, Liu et al. 2020; Inal 2020; Tobaiqy, 
Qashqary et al. 2020; Zeng, Chen et al. 2020). Unfortunately, the exact mechanisms of its 
pathogenesis remain unclear, which has made finding an effective treatment very difficult. To 
find a cure for COVID-19 we must first understand its structure and infection mechanism. 
SARS-CoV-2 is a contagious virus that can be spread through inhalation or ingestion of 
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moisture droplets that contain the virus, resulting from coughing and sneezing (Zhang, Li et al. 
2020). Structurally, SARS-CoV-2 is a single-stranded RNA virus with a genome that consists 
of ∼30000 nucleotides. This encodes four structural proteins: Nucleocapsid (N) protein, 
Membrane (M) protein, Spike (S) protein, Envelop (E) protein, and ∼16 non-structural proteins 
(nsp) (Schoeman and Fielding 2019; Boopathi, Poma et al. 2020; Jin, Du et al. 2020). The viral 
surface proteins, Spike, envelope, and membrane are embedded in a lipid bilayer enveloping a 
capsid protein shell in which there is a nucleocapsid protein (N-protein) that is bound to the 
virus's single positive-strand RNA genome (Boopathi, Poma et al. 2020). The M-protein is 
most abundant in the viral surface and it is believed to be the central organizer for the 
coronavirus assembly. The trimeric form of Spike protein is integrated across the surface of 
the virus; it mediates attachment of the virus to the host cell surface receptors and fusion 
between the viral and host cell membranes to facilitate entry into the host cell (Vinson 2020; 
Wrapp, Wang et al. 2020). The coronavirus Spike protein is subjected to proteolytic cleavage 
by host proteases (i.e. trypsin and furin) in two sites at PCS (Polybasic furin Cleavage Site) 
located at the boundary between the S1 and S2 subunits (S1/S2 site) (Fig. S1 and 9).  Binding 
of ACE2 with Spike S1 (AA: 13-685) proteins allows the virus to adhere to lung epithelial cells 
and through a tube composed of Spike S2 proteins (AA:686-1273) it injects the genetic material 
inside the host cell (Fig. S2 and S3). Once the virus reaches the budding stage, the S2 domain 
(S2′ site, AA: 816-1273) is cleaved to release the fusion peptide (Shang, Ye et al. 2020). The 
E-protein is a small membrane protein composed of ∼76 to 109 amino-acid and minor 
components of the virus particle.  It plays an important role in virus assembly, membrane 
permeability of the host cell, and virus-host cell interaction. A lipid envelope encapsulates the 
genetic material. In addition to these, Hemagglutinin-esterase dimers (HE) have been located 
at the surface of the viral capsid (Zeng, Langereis et al. 2008). Although HE proteins may be 
involved in virus entry, they are not required for replication; however, they do appear to be 
important for infecting natural host cells.  
 
With the current need to reduce the cost, time, and risks of the drug development 
process, scientists are exploring the use of already approved drug candidates to test in COVID-
19 patients such as Hydroxychloroquine, Remdesivir, and Azithromycin (Gautret, Lagier et al. 
2020; Grein, Ohmagari et al. 2020; Rosenberg, Dufort et al. 2020). The ability to reuse FDA 
approved/preclinical trial drugs to target multiple virus proteins of SARS-CoV-2 provides a 
ray of hope for the survival of humanity. In this work, we thoroughly investigated the potential 
use of broadly available antiviral, anti-bacterial, anti-parasitic drugs, flavonoids, and vitamins, 
which have shown antiviral activity. After thorough literature survey we selected these drugs 
which can be used for the treatment of COVID-19, here we explore their interaction efficiencies 
with Spike and RDRP proteins of the virus. Computational simulation is an essential tool to 
accelerate the discovery of therapeutics which can effectively cope with the rapidly evolving 
structure of SARS-CoV-2 on the molecular level (Boopathi, Poma et al. 2020). In addition, 
clinical trial reports suggest that patients suffering from COVID-19 have a low oxygen 
concentration in their blood not caused solely by respiratory distress (Kashani 2020; Wang, Hu 
et al. 2020; Xie, Covassin et al. 2020). This phenomenon led us to the hypothesis of a possible 
binding event between SARS-CoV-2’s Spike protein and the hemoglobin, specifically heme 
group interaction (Cavezzi, Troiani et al. 2020; liu and Li 2020). Further, to find out the 
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therapeutically important conservative protein motifs of the Spike protein, we performed 
multiple sequence alignments between the Spike protein sequences of SARS-CoV-2 and 75 
sequences from different virus species that belong to the Orthocoronavirinae subfamily. 
 
 
Materials and Methods 
 
1) Docking of antivirals, antibiotics, antiparasitics, flavonoids and vitamins with Spike 
and RdRp protein of SARS-CoV-2 
 
3D models of SARS-CoV-2 Spike (QHD43416.pdb) and RdRp (QHD43415_11.pdb) 
proteins were downloaded from Zhang Lab I-TESSAR online library in .pdb format (Yang and 
Zhang 2015). 3D structures of drugs and small molecules for docking were downloaded from 
PubChem in .pdb format. There was no change observed in the structure of these drug 
molecules after getting activated inside the liver, which makes them a suitable candidate for 
the docking study. Docking was performed with AutoDockTool (v1.5.6) software (Morris, 
Huey et al. 2009). All models were converted to. pdbqt format after deletion of water molecules 
and computing Gasteiger algorithm for macromolecules, whereas in ligands after choosing 
torsions ≤ 9. For developing the grid box for SARS-CoV-2 Spike protein we set the following 
metrics: X-dimension: 104, Y-dimension: 116, Z-dimension: 126, Spacing: 1.000, Offset X: 
2.917, Offset Y: 1.450 and Offset Z: 0.194 and grid were set using Autogrid4. Docking was 
performed with Autodock4, for each docking we set our macromolecules as a fixed filename 
and docked with Genetic algorithm and output set to Lamarckian GA (4.2). After the docking 
simulation, 10 docking models were analyzed and ranked by their energy binding ability (∆G). 
H-bonds were also built in the docking models and the best model of each docking was saved 
as .pdbqt format file.   
 
Docking models were further analyzed for the discovery of a binding pocket in Discovery 
Studio Visualizer (DSV) (v2019 client; Dassault Systèmes BIOVIA) software. Interactions 
were built by selecting all favorable interaction types intermolecularly. Furthermore, 2D 
diagrams were visualized through DSV. 
 
2) In silico protein-protein interaction 
 
Protein-protein docking was performed through the ClusPro (v2.0) server (Kozakov, Hall 
et al. 2017). Macromolecules were submitted in .pdb format and the most favorable model was 
downloaded for further analysis in DSV. We docked the SARS-CoV-2 Spike protein with both 
the tetramer and monomer molecules of Hemoglobin (1A3N.pdb) and the Heme group 
(extracted from 1A3N.pdb), in ClusPro server and AutoDockTools (v1.5.6) software 
respectively. LigPlot + v.2.2 software was used to generate a 2D plot of interface amino acids 
at the Hemoglobin-Spike interaction pocket (Laskowski and Swindells 2011). 
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3) Finding of most interacting motifs of Spike protein with antiviral drugs and heat-map 
representation of motifs  
 
We manually investigated the binding pocket of the Spike protein and RdRp with the 
docked drug ligands. We divided the whole protein sequence of Spike and RdRp proteins in 
12 and 10 equally spanned motifs respectively. Based on the number of interactions with the 
docked drug ligand database, we ranked each motif and further normalized the number of 
interactions in each motif to compare their potential as a target for the therapeutic drugs and 
their significance for the future drug development against SARS-CoV-2. In continuation, based 
on the normalization of the total number of interactions for each motif, heat-maps were 
produced using DSV. Similarly, we investigated the frequency and location of specific amino 
acids of Spike and RdRp in each motif, which is important for the interaction with various drug 
ligands. 
 
4) Investigation of conservative motifs of SARS-CoV-2 Spike protein and phylogenetic 
analysis 
 
To fulfill this purpose, we used the Blast Molecular Evolutionary Genetics Analysis 
(MEGA 10.0.5) tool. In the search of unique conservative regions in SARS-CoV-2 Spike 
protein throughout its evolution, we performed alignment of the amino acid sequence of the 
Spike protein with BLASTP database and selected 75 subject sequences different viruses from 
the Orthocoronavirinae subfamily (Fig.S5), which have the highest BLASTP score. Later, we 
ran the sequence alignment of these 75 subject sequences from the database using the MEGA-
X software’s MUSCLE program (Kumar, Stecher et al. 2018). Further, a phylogenetic tree was 
generated based on the Fast-Minimum Evolution tree clustering method and the Grishin 
distance method of MEGA-X. The phylogeny was tested using the resampling bootstrap 
methodology with 1000. 
 
 
Results 
 
1. Potential drugs for the treatment of COVID-19 
 
1.1.Most potent antiviral drug targeting of SARS-CoV-2 Spike protein 
 
In our study, we focused on 47 different antiviral agents (Fig. 1A) most readily available 
on the market. AutoDock based docking results suggested their interaction efficiency/binding 
efficiency with Spike protein of SARS-CoV-2 along with binding pocket and location of most 
important amino acids which are crucial for drug interaction. We have shown the top heat 
antiviral drugs based on their efficiency of interaction (Fig.2; Table S1) against the Spike 
protein; starting from the highest binding efficiency : Indinavir (∆G = -9.8 kcal/Mol), 
Nelfinavir (∆G = -9 kcal/Mol), Fosamprenavir (∆G = -8.2 kcal/Mol), Rintatolimod (∆G = -7.6 
kcal/Mol), Loviride (∆G = -7.3 kcal/Mol), Nevirapine (∆G = -7.3 kcal/Mol), Nitazoxanide (∆G 
= -7.1 kcal/Mol), Imiquimod (∆G = -6.8 kcal/Mol), Inosine (∆G = -6.5 kcal/Mol), and 
Cobicistat (∆G = -6.37 kcal/Mol). Although, most of the antivirals bind with the S1-NTD 
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region and its surroundings, which suggest they might physically block the trimeric assembly 
of the Spike protein and/or the viral adhesion to the host cell membrane via blocking the 
interaction between S1 and cell surface receptor such as ACE2. 
 
1.2.Most potent antibacterial/antiparasitic/flavonoids/vitamins for the targeting of 
SARS-CoV-2 Spike protein 
 
In our study, we focused on 21 different antibiotics, 3 antiparasitic (including 
hydroxychloroquine), 5 flavonoids, and 3 small ligands including Vitamin C and Vitamin D 
(Fig.1B); Which were proven to have some effect on other coronaviruses, and they are broadly 
accessible. Analyses of the AutoDock results yielded  a list of the top antibiotics based on their 
efficiency of interaction (Fig.3; Table S2) with the Spike protein that is as follows : 
Vancomycin (∆G = -10.2 kcal/Mol), Nelfinavir (∆G = -8.6 kcal/Mol), Azithromycin (∆G = -
7.9 kcal/Mol), Sulfamethoxazole (∆G = -6.6 kcal/Mol), Meropenem (∆G = -6.4 kcal/Mol), 
Tenofovir Disoproxil (∆G = -6.3 kcal/Mol), Trimethoprim (∆G = -6.1 kcal/Mol), Ciprofloxacin 
(∆G = -5.58 kcal/Mol), Gentamicin (∆G = -5.4 kcal/Mol), and Levofloxacin (∆G = -5.11 
kcal/Mol). 
 
Similarly, we found the top antiparasitic drugs (Fig. 1B) that interact with the Spike of 
SARS-CoV-2 (Fig.4A-4B; Table S3), which are as follows: Ivermectin B1a (∆G = -9.16 
kcal/Mol), Ivermectin B1b (∆G = -8.86 kcal/Mol), and Hydroxychloroquine (∆G = -2.85 
kcal/Mol). Furthermore, in our study, we focused on 5 different flavonoids (Fig. 1B) that were 
proven to have some effect on other coronaviruses. AutoDock results of the candidates portrays 
(Fig.4C-4D; Table S3) Tetramethoxyflavone as the peak (∆G = -4.91 kcal/Mol), with 
Herbacetin (∆G = -4.74 kcal/Mol) and Gallocatechin (∆G = -2.88 kcal/Mol) following 
afterward. Finally, we investigated the efficiency of vitamins as a therapeutic for the treatment 
of COVID-19 (Fig. 4E-4F; Table S3). We found that Vitamin D (∆G = -5.52 kcal/Mol) and 
Vitamin C (∆G = -2.95 kcal/Mol) can interact with the Spike protein. 
 
1.3. Most potent antiviral drug targeting of SARS-CoV-2 RdRp protein 
 
Our investigation included an examination of multiple drugs targeting viral RdRp and then 
comparing that to the activity of those same drugs on the Spike protein of SARS-CoV-2 (Table 
S4). We found that the top antiviral drugs having interaction with RdRp are as follows: 
Beclabuvir (∆G = -5.63 kcal/Mol), Galidesivir (∆G = -4.38 kcal/Mol), Ribavirin (∆G = -4.2 
kcal/Mol), Favipiravir (∆G = -3.09 kcal/Mol), Sofosbuvir (∆G = -2.95 kcal/Mol), Tenofovir 
(∆G = -2.34 kcal/Mol), and Remdesivir (∆G = -1.28 kcal/Mol). Most interestingly, the binding 
potential of these drugs for the interaction with Spike seems to be very similar to interaction 
with RdRp in terms of the formation of the most energetically favorable complex (Fig. 5A). As 
the subject that sparked interest in the research, Favipiravir was observed to bind to the RdRp 
molecule with an energy of -3.09 kcal in the amino acid region ranging from 380 to 510.  
Additionally, when examined against the Spike protein monomer, Favipiravir was observed to 
bind to the protein within the 620 to 650 amino acid range at a bond energy of -2.94 kcal.  
Using Favipiravir as a standard, the six most prominent RdRp-targeting drugs on the market 
were likewise examined for their binding properties.  Of the drugs examined, most stayed 
within a binding energy range of ±2.0 kcal of Favipiravir, but notably, the drug Beclabuvir 
significantly exceeded this with an energy of -5.63 kcal to the amino acid range 130 to 190 
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when binding to RdRp and -6.64 kcal to the amino acid ranges 220 to 300 and 600 to 640 when 
binding to the Spike monomer. 
 
2. Most important motifs of RdRp protein as a target for therapeutic drugs 
 
Most of the drugs targeting RdRp mainly interact between the amino acid residues 101-200 
and 701-800 specially THR-51, ASN-122, PHE-133, LYS-182, CYS-760, THR-761, ALA-
771, GLU-780 (Fig.5B).  Additionally, we also found the subtle interaction between 1-100 and 
801-900 amino acid residues. 
 
3. Most important motifs of Spike protein of SARS-CoV-2 as a target for therapeutic 
drugs 
 
Most of the antiviral drugs interact with Spike S1-NTD especially between the residues 1-
100 and 201-300 (Fig.6A). Most antiviral drug interacting residue locations at S1 are VAL-3, 
PHE-4, VAL-6, PHE-58, and PRO-82. On the other hand, most of the antiviral interaction 
occurs with Spike S2 lies between the residues 801-1000, and 1201-1300. Especially the amino 
acids ASN-824, VAL-826, THR-827, LEU-945, LYS-1205, TYR-1209, PRO-1213, and TRP-
1217 are very important. In continuation, interface residues where most of the antibiotics 
interact also lie on the S1-NTD between 1-100 and 201-300 amino acids which is similar to 
the antivirals (Fig.6B). Specifically, the residues VAL-3, VAL-6, LEU-7, LEU-8, ARG-21, 
GLN-23, LEU-24, PRO-26, PRO-82, VAL-83, and VAL-289. We also found the interaction 
pocket at S2 especially residues between 701-800, 901-1000, and 1201-1300 such as GLY-
744, ASP-745, LEU-966, VAL-976, LEU-977, ASN-978, and ARG-1000 are very important 
in the interaction with antibiotics. In addition, residues 601-700 at the junction of S1 and S2 
seem important for the action of antibiotics. 
 
Furthermore, in the case of antiparasitic drugs, we found that the residues of S2 Spike 
between 901-1000 and 1101-1200 are very important especially the locations LYS-1205 and 
TYR-1209 are similar to antivirals and antibiotics (Fig.6C). However, we also found 
interaction at S1-NTD between the residues 1-101 and 200 which suggests the therapeutic 
importance related to S1 Spike. Additionally, a study with flavonoids revealed the interaction 
at S1-NTD between the residues 1-100 especially the locations VAL-6 and ARG-21, and at S2 
between the residues 701-900 such as LYS-790, LYS-811, ALA-893 and LEU-1224 (Fig.6D). 
Similarly, the interaction with Vitamins C and D lies between the residues 1-100, 301-400, and 
501-600 amino acids of Spike S1, most importantly VAL-47, PHE-318, and THR-630, and 
between the 701-1000 residues of Spike S2 especially residues TYR-741, ILE-742, CYS-743, 
and GLY-744 (Fig.6E). 
 
4. Interaction between Hemoglobin and Heme protein with Spike of SARS-CoV-2 
 
We docked the SARS-CoV-2 Spike protein with both the molecule of hemoglobin and the 
heme group in the ClusPro (v2.0) server and AutoDockTools (v1.5.6) software, respectively. 
Taking into consideration the docking simulation of hemoglobin, both the monomer (Fig.7) 
and the tetramer (Fig. S4) of it bind very tightly to S1-NTD with several hydrogen bonds 
bridging the two molecules. Residues of the Spike protein forming hydrogen bonds with the 
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hemoglobin monomer are ARG-237, ASN-37, LEU-270, ARG-88, ASP-627, HIS-625, ASN-
61, THR-63, GLN-271, GLN-23, and TYR-28 (Fig.7). Similarly, we found that ARG-237, 
ARG-21, VAL-53, VAL-6, PHE-4, VAL-3, ASP-111, SER12, GLN-14, ARG-158, CYS-15, 
THR-22, THR-73, THR-74, GLU-132, LYS-113, and SER-112 of the Spike protein form a 
hydrogen bond with the tetramer of hemoglobin (Fig. S4). Interestingly, the ARG-237 
hydrogen bond persists in both simulations (monomer and tetramer), thus indicating a possible 
binding area that is more favorable for the interaction in terms of binding efficiency and spatial 
pairing. Moreover, the region surrounding the above-mentioned amino acid might facilitate the 
binding of the heme group to the S1-NTD region of the Spike protein. Simulation of this 
interaction was achieved through AutoDock software and yielded a binding energy score of -
5.4 kcal/Mol. Results of interaction show several Vander Waals bonds surrounding the heme 
group, whereas 6 Pi-(Anion, Sigma, -Pi Stacked and Alkyl) bonds and 1 hydrogen bond 
bridging with Spike protein (Fig.8). Amino acid residues TYR-38, LYS-41, PHE-43, LYS-
206, GLU-224, PRO-225, LEU-226, VAL-227, ASP-228, and THR-284 of Spike protein 
interact with the heme group directly. The core amino acid of this interaction is GLU-224 that 
might possess the ability to bind directly to the heme iron with a Pi-Anion bond and thus 
preventing the free oxygen-binding into the area.  
 
5. Conservative motifs of SARS-CoV-2 Spike protein and phylogenetic analysis 
correlation between the sequence of Spike protein 
 
In the search of finding unique regions in the SARS-CoV-2 Spike protein, we performed 
an alignment of the amino acid sequence of the Spike protein with the BLASTP database 
(Fig.S5). Top 5 sequences that showed high alignment scores were aligned again using MEGA-
X software and a detailed analysis of five important Spike protein domains were examined. 
Results suggest that conservation exists in higher levels at S2-HR1 and HR2, moderate 
conservation at S1-NTD, and PCS, whereas at S1-CTD there are many hypervariable regions 
(Fig. 9).  We also ran the sequence alignment of 75 subject sequences from the database using 
MEGA-X software and developed a phylogenetic tree through BLASTP. The subject 
sequences suggested by BLASTP are related to Spike proteins from MERS, Murine hepatitis 
virus (MCoV), Human coronavirus (HCoV), Feline Infectious Peritonitis virus (FIP-CoV) and 
SARS-CoV-1 (Fig. 10). Initial results suggest that the SARS-CoV-2 Spike protein shares 
similarities between SARS-CoV-1; whereas a common ancestor connects MERS and SARS-
CoV-2. The majority of similar sequences aligned with SARS-CoV-2 Spike protein are from 
the Betacoronavirus of the subspecies of Sarbecoviruses, Merbecoviruses, and Embecoviruses; 
conversely, the minority of them come from Alphacoronaviruses. 
 
For the alignment of the 75 subjected sequences, we could identify several conserved 
regions spanning throughout the protein. Several “clusters” of conserved regions spanning 
from the beginning S1-CTD until its end at the 330 to 529 amino acid range. That means S1-
CTD can be divided into 7 clusters of conserved domains, composed of around 25 amino acids 
each, according to the MEGA-X software alignment. This gives a deeper insight into the nature 
of the Spike protein Binding Domain to ACE2 and other receptors. Moreover, two massive 
evolutionarily conserved domains lie at the center of the S2 region within the amino acid ranges 
of 908 to 1003 and 1163 to 1211; indicating that the S2 part of Spike protein seems to be more 
heavily conserved compared to its S1 counterpart. In conclusion, the S1-CTD and the final 
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portion of the S2 protein are relatively conserved throughout the species and they will be 
effective references for the discovery of a universal drug against all strains of SARS-CoV-2. 
 
 
Discussion 
 
1. Importance and Significance of drug docking with Spike 
 
1.1. Antivirals 
 
At the onset of the pandemic, doctors began to try a plethora of antiviral drugs with the 
likelihood of success in an attempt to slow the progression of COVID-19 in those affected by 
the infection. However, it would be both illogical and immoral to try all of these drugs on 
human patients without any knowledge as to whether or not they will have any interaction with 
the SARS-CoV-2 virus. In our study, we focused on 47 different antivirals already approved 
and broadly available on the market that are thought to have some potential for inhibiting the 
virus.  Seeing as the Spike protein is evolutionarily conserved, it is a prime location to observe 
for interaction and inhibition of the virus in a manner that is ubiquitous across all potential 
strains.  Using the AutoDock software, we performed docking simulations between these drugs 
to observe the energy/efficiency of their interactions with the SARS-CoV-2 Spike protein.  
Arranged by their binding energy (Fig. 1A), these drugs show a wide range of effectivity from 
Saquinavir at the lowest (ΔG = -0.23 kcal/Mol) to Indinavir at the highest (ΔG = -9.8 kcal/Mol).  
Drugs with interaction energy greater than or equal to the Japanese-made Favipiravir (ΔG = -
5.2 kcal/Mol) are prime candidates to be potential treatments as it has already been observed 
to have some mild effects on inhibition of COVID-19 in patients (Wang, Cao et al. 2020). 
 
Further examination of the AutoDock results revealed that the drug molecules interacted 
with the Spike protein monomer at very specific locations (Fig. 6A).  Most notable are the β-
sheets between 1-100 residues range having over 150 different molecular interactions.  This is 
followed by the ɑ-helix between 801-900 residues range yielding over 100 unique interactions.  
Noting the location of the 1-100 range, drugs that interact with that binding pocket will most 
likely not have a large-scale effect on the protein’s functionality as it only serves as the N-
terminal domain.  Conversely, the 801-900 region is located at the point on the Spike monomer 
that is key to the formation of the Spike trimer; binding to this region would impair SARS-
CoV-2’s ability to form the trimeric structure and overall inhibit the production of viable 
virions (Vinson 2020; Wrapp, Wang et al. 2020). 
 
1.2. Antibiotics 
 
Normally, when looking at stopping a virus, antibiotics would not be considered due to 
their specific targeting of bacterial processes.  Overuse of antibiotic treatments on non-bacterial 
agents has been a major factor that has led to the rise of drug resistance (Murray 2020).  
However, all options must be considered in an emergency such as the COVID-19 pandemic 
and bioinformatics tools have the luxury to examine the potential of antibiotics being used 
against SARS-CoV-2 without the possibility of contributing to drug resistance. Additionally, 
researchers have shown the combinational therapy of Azithromycin and Hydroxychloroquine 
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suppressed the growth of SARS-Cov-2 virus in-vitro (Gautret, Lagier et al. 2020). Therefore, 
similar to our examination of antiviral drugs, we investigated the binding properties of 21 
prominent antibiotics to the SARS-CoV-2 Spike protein using the AutoDock software. After 
arranging the drugs based on their binding energy (Fig.1B), a steady increase in energy can be 
observed from Rifampicin at the lowest (ΔG = -1.83 kcal/Mol) to Vancomycin at the highest 
(ΔG = -10.2 kcal/Mol).  As was previously stated, drugs with binding energy higher than ΔG 
= -5.2 kcal/Mol exhibit inhibitory properties on the virus (as seen with Favipiravir), therefore 
9 antibiotics beginning from Gentamicin (ΔG = -5.4 kcal/Mol) have potential to disrupt viral 
function. Unfortunately, the majority of the molecular interactions observed occur in the N-
terminal domain of the Spike protein (Fig.6B) which indicates that they might yield little to no 
result in disrupting the virus. 
 
1.3. Antiparasitic 
 
Researchers have reported that Ivermectin and Hydroxychloroquine, which are FDA-
approved anti-parasitic drugs previously shown to have broad-spectrum antiviral activity in-
vitro (Gautret, Lagier et al. 2020; Heidary and Gharebaghi 2020).  Leon Caley et al. showed 
that with a single addition of Ivermectin to Vero-hSLAM cells 2 h post-infection with SARS-
CoV-2 able to effect ~5000-fold reduction in viral RNA at 48 h (Caly, Druce et al. 2020). 
Ivermectin, therefore, warrants further investigation for possible benefits in humans. Similarly, 
the 4-aminoquinoline antimalarials chloroquine and Hydroxychloroquine have been promoted 
and sometimes used in the treatment of COVID-19, alone or combined with Azithromycin, 
based on their immunomodulatory and antiviral properties, despite an absence of 
methodologically appropriate proof of their efficacy (Gautret, Lagier et al. 2020). 
  
In our study, we examined the potential for these antiparasitic drugs to interact with the 
SARS-CoV-2 Spike protein using the AutoDock software.  By comparing the binding energies 
that resulted from this analysis (Fig.1B) it can be observed that Hydroxychloroquine has a 
relatively low energy interaction (ΔG = -2.85 kcal/Mol) while Ivermectin B1a and B1b have 
high energy bonds (ΔG = -9.16 kcal/Mol and ΔG = -8.86 kcal/Mol respectively).  Additionally, 
these interactions are observed to occur primarily on the ɑ-helices existing in the 901-1200 
amino acid region of the Spike monomer (Fig. 6C).  Considering that this region is involved in 
the formation of the Spike trimer, specifically the base of Spike where protein is integrated into 
the virion and are conserved among coronavirus species (Shereen, Khan et al. 2020; Vinson 
2020; Wrapp, Wang et al. 2020). 
 
1.4. Flavonoids 
 
Neglected from the wide scientific view, flavonoids played a crucial role many times 
against emerging viruses. Tetramethoxyflavone from elderberry extract inhibited Human 
Influenza A (H1N1) infection in vitro with an IC50 value of 252 ± 34 μg/mL (Roschek, Fink 
et al. 2009). Moreover, flavonoids were utilized against the infectious bronchitis virus (IBV), 
a pathogenic chicken coronavirus (Chen, Zuckerman et al. 2014). Whereas there is a non-well 
effective vaccine yet; Chen and colleagues tested non-cytotoxic, crude ethanol extracts of 
Sambucus nigra fruit for anti-IBV activity because it contains polyphenol derivatives that 
inhibit other viruses. Electron microscopy of virions treated with S. nigra extract showed 
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compromised envelopes and the presence of membrane vesicles, which suggested a mechanism 
of action. These results demonstrate that S. nigra extract can inhibit IBV at an early point in 
infection, probably by rendering the virus non-infectious. They also suggest that future studies 
using S. nigra extract to treat or prevent IBV or other coronaviruses are warranted (Chen, Zheng 
et al. 2014). Additionally, coronaviruses of SARS and MERS have been rising targets of some 
flavonoids. The antiviral activity of some flavonoids against CoVs is presumed directly caused 
by inhibiting 3C-like protease (3CLpro). It has been suggested that flavonoids such as 
herbacetin, rhoifolin, and pectolinarin were found to efficiently block the enzymatic activity of 
SARS-CoV 3CLpro (Jitendra Subhash, Aroni et al. 2020; Jo, Kim et al. 2020).  
 
In our study, we focused on 5 different flavonoids (Fig.1) that were proven to have some 
effect with other coronaviruses. AutoDock results of the candidates suggested a top hit of 
Tetramethoxyflavone (∆G = -4.91 kcal/Mol) and a second top hit being Herbacetin (∆G = -
4.74 kcal/Mol). Although they did not exhibit high ∆G values, flavonoids showed unique 
binding areas. From the binding areas, we could roughly identify the preferent binding regions 
on the Spike protein (Fig.5). Total interactions per segment results suggest a tendency of 
flavonoids to bind in both S1-NTD and S2. Even though most of the screened drugs and small 
molecules bind with the S1-NTD region, flavonoids showed an increased number of 
interactions in the conserved S2 region too. This suggests that they might possess the ability 
not only for structurally inhibiting the assembly of the Spike trimer but also for binding into 
the lumen of the trimeric protein and thus inhibiting the viral fusion with the host cell in a 
variety of coronaviruses.  
 
 
1.5. Vitamins 
 
Earlier, researchers claimed that vitamin C has a beneficial effect on asthma. In the absence 
of a specific treatment for SARS, the possibility that vitamin C may show non-specific effects 
on severe viral respiratory tract infections should be considered (Hemilä 2003). Numerous 
reports are indicating that vitamin C may affect the immune system for example the function 
of phagocytes, transformation of T lymphocytes, and production of interferon (Leibovitz and 
Siegel 1981; Hemilä and Douglas 1999). In particular, vitamin C increased the resistance of 
chick embryo tracheal organ cultures to infection caused by an avian coronavirus (Atherton, 
Kratzing et al. 1978). Studies in animals found that vitamin C modifies susceptibility to various 
bacterial and viral infections, for example protecting broiler chicks against an avian 
coronavirus. Five placebo-controlled trials have shown quite consistently that the duration and 
severity of common cold episodes are reduced in the vitamin C groups, indicating that viral 
respiratory infections in humans are affected by vitamin C levels. There is also evidence 
indicating that vitamin C may affect pneumonia (Hemilä 1997). In particular, three controlled 
trials with human subjects reported a significantly lower incidence of pneumonia in vitamin C-
supplemented groups, suggesting that vitamin C may affect susceptibility to lower respiratory 
tract infections under certain conditions.  
 
Similarly, the role of Vitamin D has been proved very important for the prevention of lower 
respiratory tract diseases caused by viral infections. There are two forms of vitamin D, 
cholecalciferol (vitamin D3), and ergocalciferol (vitamin D2) (Yang, Lv et al. 2019). Vitamin 
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D has also been implicated as a causal factor for the common cold (Rondanelli, Miccono et al. 
2018). Two observations point in this direction. Colds are more frequent in the winter when 
vitamin D levels are generally lower, and patients with chronic obstructive pulmonary disease 
who have lower levels of vitamin D have more upper respiratory tract infections (URIs). Citing 
the role of vitamin D, Gindi et al found that the number of recent URIs was inversely related 
to serum 25(OH)D levels; this linkage was stronger in patients with pre-existing respiratory 
tract disease (Ginde, Mansbach et al. 2009). On a more positive note, the Cochrane 
Collaborators' review of vitamin D for asthma is quite encouraging (Martineau, Cates et al. 
2016). Recently, researchers found an association between mean levels of vitamin D in various 
countries and cases respectively mortality caused by COVID-19. Their results suggested that 
the mean level of vitamin D (average 56mmol/L, STDEV 10.61) in each country was strongly 
associated with the number of cases/1M (mean 295.95, STDEV 298.73 p=0.004, respectively 
with the mortality/1M (mean 5.96, STDEV 15.13, p < 0.00001) (Ilie, Stefanescu et al. 2020). 
Vitamin D levels are severely low in the aging population, especially in Spain, Italy, and 
Switzerland. This is also the most vulnerable group of the population for COVID-19. In 
addition to that, in the present study, we also found that vitamin C (∆G = -2.95 kcal/Mol) and 
vitamin D3 (∆G = -5.52 kcal/Mol) can directly interact with Spike protein of SARS-CoV-2 
(Fig. 4E-4F). This finding lends the idea that vitamin C and vitamin D both can block the 
binding of Spike with host cell receptors, the formation of its trimeric form and fusion to host 
cells make them important candidates for further clinical trials to probe their potential for the 
treatment of lower respiratory tract diseases.  
 
 
2. Importance and Significance of drug docking with RdRp 
 
During the early stages of the SARS-CoV-2 pandemic, doctors scrambled to find an 
effective treatment for those suffering from the virus.  Among the many drugs used in an 
attempt to slow the virus, the Japanese anti-influenza drug Favipiravir (sold as Avigan) showed 
promise when applied to COVID-19 patients. This is believed to be through its inhibition of 
the RNA-dependent RNA polymerase (RdRp) employed by RNA viruses during their 
replication process (Furuta, Komeno et al. 2017; Cai, Yang et al. 2020).  However, as the 
pandemic wore on it became clear that this drug was only effective when administered at early 
stages of coronavirus infection; a phenomenon observed in tests against other viruses including 
alphaviruses, arenaviruses, and flaviviruses (Furuta, Komeno et al. 2017).  This suggests that 
the inhibition of RdRp works primarily as a preventative measure rather than a primary form 
of treatment against RNA-based viruses. Further, our findings suggest the efficacy of 
Beclabuvir, in particular, to be used against SARS-CoV-2.  Not only does it interact 
significantly with the viral RdRp, but it’s binding energy to the Spike protein exceeds that of a 
significant number of the drugs tested in this study.  This suggests that it would have a stronger 
inhibitory factor to the virus than that of Favipiravir and provide additional protection in the 
form of disrupting the Spike protein’s function. 
In our investigation, we examined 7 antiviral drugs known to primarily interact with RdRp 
in their respective viral targets.  Using the AutoDock software to generate docking simulations 
of these drugs to the SARS-CoV-2 RdRp molecule, the drugs were arranged according to their 
binding energies (Fig. 5A). Using Favipiravir as a standard at ΔG = -3.09 kcal/Mol for the 
ability to exhibit a mild clinical success, 3 RdRp-targeting drugs are immediately identifiable 
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as potentially more successful: Ribavirin (ΔG = -4.20 kcal/Mol), Galidesivir (ΔG = -4.38 
kcal/Mol), and Beclabuvir (ΔG = -5.63 kcal/Mol). Additional examination of where these 
molecular interactions take place revealed that they are primarily concentrated in the 101-200 
and 701-800 amino acid regions (Fig. 5B).  Similar to the Spike protein, the 701-800 regions 
in particular consist of a series of ɑ-helices that are essential in the RdRp’s functionality; 
blocking them would, therefore, inhibit the use of RdRp and essentially shut down the virus’s 
ability to replicate its genome. 
 
3. Significance of Heme/hemoglobin and Spike interactions 
Recently many anecdotal clinical trial reports suggest that patients affected by COVID-19 
not only have impaired respiratory function but also low oxygen count causing respiratory 
distress (Li and Ma 2020; Wang, Hu et al. 2020; Xie, Covassin et al. 2020). This phenomenon 
led us to the hypothesis of a possible binding event between SARS-CoV-2 Spike protein and 
the heme group of the hemoglobin molecule. That binding might greatly reduce the oxygen 
affinity to hemoglobin and increase its degradation rate as many COVID-19 survivors showed 
much less hemoglobin count compared with the non-infected (Cavezzi, Troiani et al. 2020; liu 
and Li 2020). It was also revealed that alternative treatments currently being considered for 
COVID-19 such as Chloroquine and Hydroxychloroquine by increasing hemoglobin 
production and increasing hemoglobin availability for oxygen binding and acetazolamide by 
causing hyperventilation with associated increasing levels of oxygen and decreasing levels of 
carbon dioxide in the blood may significantly ameliorate COVID-19 respiratory symptoms 
(Iyamu, Perdew et al. 2009; Pastick, Okafor et al. 2020). 
 
Considering the docking simulation of hemoglobin, Spike protein has the possible potential 
to interact with the tetramer and monomer of it (Fig.7). Amino acid GLU224 might be the key 
target as it plays a crucial role of binding directly to the iron particle of heme group. This is the 
first time shown that the Spike protein of SARS-CoV-2 might interact with not only the 
hemoglobin molecule but as well as with the heme group directly to its iron particle. These 
results will shed light on the, yet inkown, intrinsic mechanism of SARS-CoV-2 Spike protein 
and the low oxygen count of patients and survivors, whereas at the same time offers a possible 
target side for the development of new drugs. 
 
4. Alignment and drug comparison: 
 
We also identified conserved regions through the sequence alignment and found several 
portions of the protein that have some conservation among similar species Spike proteins. 
Starting from S1-NTD, 10 out of 75 subjected sequences match with its first portion at 1-200 
amino acid range, whereas 24 out of 75 sequences match with the S1-NTD’s last portion at 
201-300. A moderate amount of similarity was observed at the S1-CTD side with 33 similar 
sequences at around 300-510. Moreover, the highest conservation among subjected sequences 
was observed in the center of the S2 portion of the protein at around 900-1000 in a number of 
42 from 75 (Fig. S5). To strengthen these results, we aligned 5 Spike proteins among several 
species related to coronavirus (Porcine epidemic virus, MERS-CoV, FIP-CoV, SARS-CoV-1, 
and Human-CoV) and investigate their conservation in five core domains (S1-NTD, S1-CTD, 
PCS, S2-HR1, and S2-HR2). Domains of S1-NTD, HR1, and HR2 showed high conservation 
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(Fig. 9). This might suggest that drugs which tend to bind to those regions are more effective 
in addressing a bigger spectrum of coronaviruses. Interestingly, most of the antiviral top hit 
drugs like Indinavir (ΔG= -9.8 kcal/Mol) and Nelfinavir (ΔG= -9 kcal/Mol) are binding near 
the center of S2 (Fig. 2). The similar pattern observed with antiparasitic drugs Ivermectin B1a/b 
(ΔG= -9.16/-8.86 kcal/Mol) (Fig. 4A-4B) and Vitamin D (ΔG= -5.52 kcal/Mol) (Fig. 4E-4F), 
whereas on the other hand, top hit antibiotic drugs did not show preferences at the S2 binding 
area of the Spike protein (Fig. 4). In this perspective, the above-mentioned drugs could possess 
the ability to physically inhibit the assembly of the Spike protein as well as the viral entry in a 
pan-CoV targeted manner.  
 
Shuai and colleagues (Xia, Yan et al. 2019) showed that targeting the HR1 domain of 
Human-CoV Spike protein, which is in the area of S2, that showed increased binding with our 
docked drugs, significantly reduced the viral entry in mouse models. Targeting this specific 
domain with a small molecule could be a pan-CoV target as its conservation is high among the 
CoV species. Turning the attention to conserved areas of Spike protein and not to the 
hypervariable S1-CTD will lead to a drug that not only has great inhibitory potential but also 
will possess a broad target activity against multiple coronavirus infection.  
 
Moreover, taking into consideration another spotlight region of the Spike protein, the 
Polybasic furin Cleavage Site (PCS), which located in the boundaries of S1 and S2, was under 
our observations (Andersen, Rambaut et al. 2020).Throughout our docked library only one 
molecule could bind into that area. Vancomycin which exhibited the lowest binding energy 
(∆G = -10.2 kcal/Mol) from all our docked drug categories, is the only drug that binds within 
the region of PCS in an approximate position of amino acid range between 654 and 692. The 
functional activity is still unknown for SARS-CoV-2 PCS; pathogenicity and transmissibility 
need to be elucidated as well. Emerging research referred to PCS as an enhancer of cell-cell 
fusion, whereas cleavage of it results in intra-species infection; with a great example of MERS-
CoV (Menachery, Dinnon et al. 2020). Thus, it is very important to evaluate drugs that can 
bind to that area of the Spike protein since it might result in wanting outcomes for the fight 
against SARS-CoV-2. 
 
 
Conclusion 
 
In the present study, docking of common antiviral, antibiotics, antiparasitic, and other 
ligands such as flavonoids and vitamins to SARS-Cov-2 core proteins (Spike and RdRp) 
revealed the potential of their use for the treatment of COVID-19 during the current emergency. 
Drugs Indinavir, Nelfinavir, Vancomycin, Gliclazide, Ivermectin, Vitamin C, and Vitamin D, 
showed very high affinity, thus can be used as a potential therapeutic in the current pandemic. 
However, in-vitro and in-vivo clinical trials are needed to further evaluate the potential of these 
drugs alone or in combination for the treatment of COVID-19. In addition, the finding of most 
interacting motifs of Spike and RdRp, altogether with conservative motifs of SARS-CoV-2 
Spike throughout the evolution gives a new layer of understanding of the computer-aided drug 
and antibody/vaccine designing for the treatment of COVID-19. Our study suggests there is a 
high possibility of mutation in the S1 region of the Spike protein, in contrary S2 remains more 
conservative during the evolution. Therefore, the use of a combination of conserved peptide 
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sequences of Spike protein could be a strategy to develop an effective vaccine. Additionally, 
designing the new drugs selectively targeting these conservative motifs might help to find out 
a potential cure for the COVID-19. However, an in-vitro/in-vivo investigation will be needed 
for the further clinical use of the results of present study. Finally, designing of inhibitory 
peptides blocking the receptor-binding domain of Spike protein interacting with 
hemoglobin/heme that we reported in the current study, could help to control the hypoxia 
condition during the infection of SARS-Cov-2, which might significantly improve the survival 
of patients suffering from COVID-19. 
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Fig.1: Circular tree represents the order of antiviral drugs (A) and antibiotics, antiparasitic, 
flavonoids, and extra ligands (B) based on the binding energy (∆G in kcal/Mol). 
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Fig.2: 2D interaction plot shows interface amino acid of Spike to top hit antiviral drugs 
Indinavir (A), Nelfinavir (B), Fosamprenavir (C), Ritatolimod (D), Loviride (E) and 
Nevirapine (F). ∆G is the binding energy of the drug ligand in kcal/Mol. 
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Fig.3: 2D interaction plot shows interface amino acid of Spike to top hit antibiotics. 
Vancomycin (A), Gliclazide (B), Azithromycin (C), Sulfamethoxazole (D), Meropenem (E), 
and Tenofovir (F). ∆G is the binding energy of the drug ligand in kcal/Mol. 
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Fig.4: 2D interaction plot shows interface amino acid of Spike to top hit antiparasitic drugs (A 
and B), flavonoids (C and D), and vitamins (E and F). ∆G is the binding energy of the drug 
ligand in kcal/Mol. 
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Fig.5: A graphical representation of the comparative analysis found in Table S4.  Binding 
energies are organized here (A) are arranged from weakest to strongest based on the molecule 
it is interacting with.  These lists of drugs and their binding energies are separated along the 
27 
 
central axis based on the viral protein they are interacting with, namely RdRp on the left and 
the Spike protein on the right-hand side.  Additionally, quantitative analysis and graphical 
representation of the locations at which the molecules are interacting with the SARS-CoV-2 
RdRp (B) can be observed. 
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Fig.6: Heat map of the Spike protein represents the frequency of antiviral drug bindings against 
the 12 segments of the protein. Simulations suggest a preference of antiviral drugs to bind 
around the S1-NTD region and S2(A); were similar results observed in flavonoid interactions 
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(D). Docking of antibiotic drugs exhibits a preference in the S1-NTD region only (B). 
Antiparasitic drugs interestingly showed a higher binding frequency in S2 of the protein (C). 
From the perspective of the vitamins, they showed to bind in both S1-NTD/–CTD region and 
S2 (E). 
 
 
Fig.7: 3D representation of the interaction between the Spike protein (in yellow color) and 
hemoglobin monomer (in magenta color) (A). 2D interaction plot was formed via LigPlot. The 
interaction may occur at S1-NTD with the referred amino acids from each side. Hydrogen 
bonds are represented by the green dashed lines (B). 
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Fig.8: Spike protein (in yellow color) docked with hemoglobin heme group near the S1-NTD 
(A). 2D interaction plot of the interaction, whereas GLU224 seems to play a central role in this 
interaction via direct binding with the iron particle of heme. The binding energy of this reaction 
was calculated at -5.4 kcal/Mol (B). 
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Fig.9: SARS-CoV-2 Spike protein 3D structure with the important domains depicted with 
colors; S1-N Terminal Domain (orange), S1-C Terminal Domain/ ACE2 Binding Domain 
(yellow), Polybasic Cleavage Site (purple), S2 Heptad repeat 1 (blue) and S2 heptad repeat 2 
(green) (A). SARS-CoV-2 Spike protein 2D representation. Important domains are magnified, 
and their alignment sequences are shown beneath them. Each alignment box consists of 1 to 3 
lanes (a., b., c.), whereas the starting amino acid is shown at the top left, and ending amino acid 
is shown at the bottom right of each alignment box. Each lane consists of 6 sequences subjected 
to the alignment (n.). Conservation exists in higher levels at S2-HR1 and HR2, moderate 
conservation is observed at S1-NTD and PCS, and at S1-CTD there are many hypervariable 
regions (B). 
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Fig.10: Phylogenetic tree of various coronavirus particles whose sequences align with SARS-
CoV-2 Spike protein in the BLASTP server. Cartoon of the animal for each CoV species 
represents the carrier of the disease, whereas the secondary smaller animal represents the 
species that have been originated from if it is known. 
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Fig. S1: 3D protein structure of the SARS-CoV-19 Spike protein in its trimeric form. Each monomer is colored 
with a different color (magenta, blue, and green) (A). Top view of the trimeric Spike protein (B). 3D protein 
structure of SARS-CoV-19 RdRp (C). 3D protein structure of a dimer of human ACE2 receptor (D).  
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Fig. S2: Interaction of the trimeric SARS-CoV-19 Spike protein with the dimeric ACE2 receptor using the 
ClasPro server. Interaction is happening at the S1-CTD of the Spike protein (A). Interacting amino acids of each 
protein responsible for the interaction visualized by Ligplot. Green dashed lines between the opposing amino 
acids represent hydrogen bonds, whereas arches represent other forces (i.e. Van der Waals forces) (B). 
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Fig. S3: Interaction of the monomeric SARS-CoV-19 Spike protein with the monomeric ACE2 receptor using 
the ClasPro server. Interaction is happening at the S1-CTD of the spike protein (A). Interacting amino acids of 
each protein responsible for the interaction visualized by Ligplot. Green dashed lines between the opposing 
amino acids represent hydrogen bonds, whereas arches represent other forces (i.e. Van der Waals forces) (B). 
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Fig. S4: 3D representation of the interaction between the Spike protein (in yellow color) and hemoglobin 
tetramer (in magenta color) (A). 2D interaction plot was formed via LigPlot. The interaction may occur at S1-
NTD with the referred amino acids from each side. In green dashed lines represent hydrogen bonds between the 
interactive amino acids (B).  
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Fig. S5: Schematic represents a graphic summary of the alignment result in the BLASTP server. Query 
represents the SARS-CoV-2 Spike protein sequence aligned with 83 BLAST hits with a color grading system as 
the alignment score scale (black <40, blue 40-50, green 50-80, magenta 80-200 and red ≥200) (A). The table 
represents a taxonomical lineage of organisms possessing similar proteins as SARS-CoV-2 Spike protein. The 
number of hits represents the number of similar sequences compared with our query sequence. 
Orthocoronavirinae exhibits the highest number of hits followed by Betacoronavirus and Sarbecovirus (B). 
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Table S1: List of the ten top hits of antiviral drugs against SARS-CoV-2 Spike protein by order of lowest to 
highest binding energy value. Indinavir seems to exhibit the lowest binding energy (-9.8 kcal/Mol) when 
docked with Spike protein, whereas Cobicistat exhibits the highest binding energy (-6.37 kcal/Mol).  
 
 Antivirals Binding 
energy 
(kcal/Mol) 
2D interaction Interface 
amino 
acids 
Type of 
interactions 
1 Indinavir (C36H47N5O4), 
5362440 
-9.8  
 
Ala, 2Arg, 
Asn, 2Asp, 
Gln, Glu, 
2Ile, 4Leu, 
2Lys, Phe, 
Pro, Ser, 
Thr, 2Trp, 
Tyr 
1Alk, 1CHB, 
2HB, 1Pi-An, 
3Pi-Alk, 1Pi-
Cat, 2Pi-
Sig,1Pi-Pi-T, 
14VW 
2 Nelfinavir (C32H45N3O4S), 
64143 
-9  
 
2Arg, Gln, 
5Leu, 
3Phe, 
2Pro, Thr, 
3Val 
3HB, 5Pi-
Alk, Pi-Pi-
Stk, 7VW, 
1UDD, 1UPP 
3 Fosamprenavir 
(C25H36N3O9PS), 131536 
-8.2  
 
 
Ala, Asn, 
3Asp, 
5Phe, 
2Leu, Lys, 
Ser, 3Val 
1AC, 2Alk, 
1HB, 1Pi-
Alk, 1Pi-Pi-
Stk, 1Pi-Sig, 
1UPP, 11VW 
4 Rintatolimod 
(C28H40N9O25P3), 
135537060 
-7.6  
 
 
Arg, 3Asn, 
2Asp, 
2Gln, 
2Glu, Gly, 
2Ile, 2Lys, 
Pro, 2Ser, 
1Val 
1AC, 1CHB, 
5HB, 14VW 
5 Loviride (C17H16Cl2N2O2), 
3963 
-7.3  Ala, Asn, 
3Asp, Leu, 
2Alk, 1CHB, 
3HB, 1Pi-Pi-
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Lys, 4Phe, 
Ser, Thr, 
2Val 
Stk, 1Pi-Sig, 
9VW 
6 Nevirapine (C15H14N4O), 
4463 
-7.3  
 
Ala, Asn, 
2Ile, 2Leu, 
Phe, Pro, 
Thr, 2Trp,  
Tyr, Val 
1CHB,12VW 
7 Nitazoxanide 
(C12H9N3O5S), 41684 
-7.1  
 
2Arg, Asn, 
2Gln, Phe, 
Pro, 4Leu, 
3Val 
4HB,12Pi-
Alk, 1Pi-Sig, 
9VW 
8 Imiquimod (C14H16N4), 
57469 
-6.8  
 
Asn, Ile, 
2Leu, Lys, 
Phe, Pro, 
Thr, Trp, 
Tyr, Val 
2Alk, 2HB, 
1Pi-Alk, 
5VW 
9 Inosine (C10H12N4O5), 
135398641 
-6.5  Arg, Asp, 
5Leu, 
2Phe, Pro, 
3Val 
2HB, 12VW 
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10 Cobicistat (C40H53N7O5S2), 
25151504 
-6.37  
 
1Ala, 
1Asn, 
1Gly, 1Ile, 
3Leu, 
2Lys, 
2Phe, 
1Pro, 2Ser, 
2Thr, 
2Trp, 
1Tyr, 1Val 
2HB, 7Pi-
Alk, 14VW 
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Table S2: List of the ten top hits of antibiotics drugs against SARS-CoV-2 Spike protein by order of lowest to 
highest binding energy value. Vancomycin seems to exhibit the lowest binding energy (-10.2 kcal/Mol) when 
docked with Spike protein, whereas Levofloxacin exhibits the highest binding energy (-5.11 kcal/Mol).  
 
 Antibiotics Bindin
g 
energy 
(kcal/
Mol) 
2D interaction Interface amino acids Type of 
interactions 
1 Vancomycin 
(C66H75Cl2N9O24
), 14969 
-10.2 
 
2Ala, Asn, Asp, 3Gln, Glu, Gly, 
Ile, 2Leu, Lys, 3Phe, 3Ser, 3Thr, 
2Val 
5HB, 1Pi-Alk, 
1Pi-DHB, 1Pi-
Pi-T, 1Pi-Sig, 
17VW 
2 Gliclazide 
(C15H21N3O3S), 
3475 
-8.6 
 
Ala, Asn, 2Asp, 2Leu, Lys, 3Phe, 
Ser, 2Val 
3Alk, 1HB, 
1Pi-Alk, 1Pi-
Sig, 9VW 
3 Azithromycin 
(C38H72N2O12), 
447043 
-7.9 
 
2Arg, 2Asn, Asp, Gly, 2Leu, Met, 
Phe, 4Ser, Tyr, 3Val 
2Alk, 1CHB, 
3HB, 13VW 
4 Sulfamethoxazole 
(C10H11N3O3S), 
5329 
-6.6 
 
Arg, Asn, Asp, Gln, 5Leu, Phe, 
Pro, Thr, 3Val 
3Alk, 2HB, 
3Pi-Alk, 1Pi-
Sig, 9VW 
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5 Meropenem 
(C17H25N3O5S), 
441130 
-6.4 
 
Ala, Asn, 3Asp, 2Leu, 2Lys, 4Phe, 
Ser, Thr, 2Val 
1CHB, 2HB, 
15VW 
6 Tenofovir 
Disoproxil 
(C19H30N5O10P), 
5481350 
-6.3 
 
2Arg, Asn, 2Gln, 5Leu, Met, 2Phe, 
2Pro, Thr, 3Val 
2Alk, 1CHB, 
2HB, 1UDD, 
16VW 
7 Trimethoprim 
(C14H18N4O3), 
5578 
-6.1 
 
Arg, Asp, Gln, 2Leu, Met, 2Phe, 
2Pro, Thr, Tyr, 3Val 
2Alk, 2CHB, 
1Pi-Alk, 1Pi-
Sig, 12VW 
8 Ciprofloxacin 
(C17H18FN3O3), 
2764 
-5.58 
 
2Asn, 1Gln, 2Glu, 1Lys, 1Phe, 
1Pro, 1Thr, 1Tyr, 1Val 
3CHB, 1Hal, 
3HB, 1Pi-Pi-T, 
1Pi-Sig, 4VW 
9 Gentamicin 
(C21H43N5O7), 
3467 
-5.4 
 
Arg, Asn, Asp, Cys, Gly, Ile, 2Leu, 
Met, Phe,Tyr, Val 
5HB, 8VW 
10 Levofloxacin 
(C18H20FN3O4), 
149096 
-5.11 
 
2Asn, 1Gn, 2Glu, 1Lys, 1Phe, 
1Pro, 1Thr, 1Tyr, 1Val 
5CHB, 2HB, 
1Pi-Alk, 4VW 
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Table S3: List of the top hits antiparasitic drugs, flavonoids, and Vitamins against SARS-CoV-2 Spike protein 
by order of lowest to highest binding energy value. Ivermectin B1a seems to exhibit the lowest binding energy 
(-9.16 kcal/Mol) when docked with Spike protein, whereas Hydroxychloroquine exhibits the highest binding 
energy (-2.85 kcal/Mol). In terms of flavonoids Tetramethoxyflavone exhibit, the lowest binding energy (-4.91 
kcal/Mol) and Gallocatechin exhibits the highest binding energy (-2.88). Moreover, Vitamin D showed the 
lowest binding energy (-5.52 kcal/Mol) and Vitamin C the lowest binding energy (-2.95 kcal/Mol). 
 
 Antiparasitic Binding 
energy 
(kcal/Mol) 
2D interaction Interface amino 
acids 
Type of 
interactions 
1 Ivermectin B1a 
(C48H74O14), 
6321424 
-9.16 
 
1Arg, 2Asn, 1Asp, 
2Gly, 1His, 3Ile, 
2Lys, 1Ser, 1Tyr, 
4Val 
4Alk, 1CHB, 
2Pi-Alk, 
1UPP, 12VW 
2 Ivermectin B1b 
(C47H72O14), 
6321425 
-8.86 
 
3Asn, 2Gln, 1Glu, 
1Gly, 1Ile, 3Leu, 
4Lys, 1Pro, 2Thr, 
1Tyr, 1Val 
2AC, 3Alk, 
1CHB, 1Pi-
Alk, 14VW 
3 Hydroxychloroquine 
(C18H26ClN3O), 
3652 
-2.85 
 
Asn, 3Asp, Gln, 
Gly, 2Ile, Leu, 
Lys, Phe, Pro 
2Alk, 1HB, 
9VW 
 
 
 Flavonoids Binding 
energy 
(kcal/Mol) 
2D interaction Interface amino 
acids 
Type of 
interactions 
1 Tetramethoxyflavone 
(C19H18O6), 471721 
-4.91 
 
2Ala, 1Gln, 1Gly, 
1Ile, 2Lys, 1Phe, 
1Tyr, 1Val 
2CHB, 2HB, 
3Pi-Alk, 1Pi-
Sig, 5VW 
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2 Herbacetin 
(C15H10O7), 
5280544 
-4.74 
 
1Arg, 1Asn, 1Asp, 
1Gln, 4Leu, 2Phe, 
1Pro, 1Thr, 3Val 
4HB, 4Pi-Alk, 
1Pi-Cat, 1Pi-
DHB, 9VW 
3 Gallocatechin 
(C15H14O7), 65084 
-2.88 
 
1Arg, 1Asn, 1Asp, 
1Glu, 1Ile, 3Leu, 
2Lys, 1Ser, 2Phe, 
2Pro, 1Val 
2Alk, 3HB, 
4Pi-Alk, 
10VW 
 
 Vitamins Binding 
energy 
(kcal/Mol) 
2D interaction Interface amino 
acids 
Type of 
interactions 
1 Vitamin D 
(C27H44O), 5280795 
-5.52 
 
 2Arg, Asp, Cys, 
Gly, Ile, 2Leu, 
Met, 2Phe, 2Ser, 
Tyr, 3Val 
3Alk, 1HB, 
12VW 
2 Vitamin C (C6H8O6), 
54670067 
-2.95 
 
Arg, Asn, Gly, 
2Phe, Thr, Val 
4HB, 5VW 
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Table S4: A comparative analysis between SARS-CoV-2 RdRP binding affinities and spike protein binding 
affinities in antivirals which primarily target viral RdRP.  These comparisons include binding energy, the 
specific amino acids that are interacting with the drug, and the types of bonds formed during this interaction. 
 
 Name and 
PubChem 
ID 
Bound 
molecule 
Binding 
Energy 
(kcal) 
2D Interaction 
Plot 
Interface Amino Acid Type of 
Interactions 
1 Beclabuvir 
(C36H45N5
O5S), 
49773361 
RdRp -5.63 
 
2Ala, 2Asn, Asp, Leu, Lys, 
Met, 2Pro, Ser, Trp 
4HB, 2Pi-Alk, 
1Pi-Pi-T, 
8VW 
  Spike -6.64 
 
Ala, Asn, 3Asp, Gln, 2Leu, 
4Phe, Ser, 2Thr, 3Val 
2Alk, 2CHB, 
1Pi-Alk, 2Pi-
Pi-T; 12VW 
2 Galidesivir 
(C11H15N5
O3), 
10445549  
RdRp -4.38 
 
2Asp, Cys, Glu, Leu, Phe, 
2Ser 
1CHB, 6HB, 
1Pi-Alk, 1Pi-
Ani, 2VW 
  Spike -3.11 
 
Asp, Glu, Pro, Ser 3HB, 2Pi-Alk, 
1Pi-An 
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3 Ribavirin 
(C8H12N4O
5), 37542 
RdRp -4.2 
 
2Ala, Arg, Asp, Ile, Leu, Lys, 
2Phe, Val 
5HB, 2Pi-Alk, 
1Pi-Cat, 1Pi-
Pi, 4VW 
  Spike -3.29 
 
Arg, Cys, Gly, Ile, Leu, Phe, 
Pro, 3Thr 
3HB, 7VW 
4 Favipiravir 
(C5H4FN3
O2), 492405  
RdRp -3.09 
 
Gly, His, Leu, Lys, 3Met, 
Phe, Ser, Thr 
1CHB, 1Hal, 
4HB, 1Pi-Alk, 
1Pi-Sul, 5VW 
  Spike -2.94 
 
Gly, His, Ile, Pro, Ser, Thr, 
Tyr, Val 
1CHB, 4HB, 
1Pi-Alk, 4VW 
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5 Sofosbuvir 
(C22H29FN
3O9P), 
45375808 
RdRp -2.95 
 
Ala, His, Lys, Phe, 3Ser, Thr 1Alk, 2HB, 
2Pi-Alk, 
3VW, 1UPP 
  Spike -3.7  Arg, Asn, Gln, Gly, Ile, Phe, 
Pro, Ser, Thr 
1APS, 2HB, 
1Pi-DHB, 
5VW 
6 Tenofovir 
(C9H14N5O
4P), 464205 
RdRp -2.34 
 
Ala, 3Asn, 2Asp, Gly, His, 
Lys, 2Ser 
1CHB, 3HB, 
1Pi-Alk, 9VW 
  Spike -2.75 
 
Lys, 2Trp, 2Tyr 1CHB, 1HB, 
2Pi-Alk, 1Pi-
Cat, 2Pi-Pi-
Stk, 2VW 
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7 Remdesivir 
(C27H35N6
O8P), 
121304016 
RdRp -1.28 
 
2Gln, 2Glu, Ile, 2Leu, Lys, 
Pro 
1Alk, 1CHB, 
1HB, 4Pi-Alk, 
5VW, 1UPP 
  Spike -2.65 
 
2Arg, 4Leu, 2Phe, 1Pro, 3Val 4Alk, 1CHB, 
3HB, 1Pi-Pi-
T, 1Pi-Pi-Stk, 
1Pi-Sig, 4VW 
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